These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 33240585)

  • 1. Use and effectiveness of dapagliflozin in patients with type 2 diabetes mellitus: a multicenter retrospective study in Taiwan.
    Chen JF; Peng YS; Chen CS; Tseng CH; Chen PC; Lee TI; Lu YC; Yang YS; Lin CL; Hung YJ; Chen ST; Lu CH; Yang CY; Chen CC; Lee CC; Hsiao PJ; Jiang JY; Tu ST
    PeerJ; 2020; 8():e9998. PubMed ID: 33240585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Dapagliflozin on Glycemic Control, Weight, and Blood Pressure in Patients with Type 2 Diabetes Attending a Specialist Endocrinology Practice in Canada: A Retrospective Cohort Analysis.
    Brown RE; Gupta N; Aronson R
    Diabetes Technol Ther; 2017 Nov; 19(11):685-691. PubMed ID: 28829163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in HbA1c, body weight, and systolic blood pressure in type 2 diabetes patients initiating dapagliflozin therapy: a primary care database study.
    Scheerer MF; Rist R; Proske O; Meng A; Kostev K
    Diabetes Metab Syndr Obes; 2016; 9():337-345. PubMed ID: 27822077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of Dapagliflozin as Add-On to Metformin with or without Other Oral Antidiabetic Drugs in Type 2 Diabetes Mellitus: A Multicentre, Retrospective, Real-World Database Study.
    Sethi B; Sahay R; Tiwaskar M; Negalur V; Dhediya R; Gaurav K; Rathod R; Kotak B; Dhanaki G; Shah S
    Drugs Real World Outcomes; 2024 Mar; 11(1):81-90. PubMed ID: 37898577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycated Hemoglobin, Body Weight and Blood Pressure in Type 2 Diabetes Patients Initiating Dapagliflozin Treatment in Primary Care: A Retrospective Study.
    Wilding J; Bailey C; Rigney U; Blak B; Beekman W; Emmas C
    Diabetes Ther; 2016 Dec; 7(4):695-711. PubMed ID: 27585582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension.
    Leiter LA; Cefalu WT; de Bruin TW; Gause-Nilsson I; Sugg J; Parikh SJ
    J Am Geriatr Soc; 2014 Jul; 62(7):1252-62. PubMed ID: 24890683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dapagliflozin improves cardiovascular risk factors in Emirati patients with T2DM.
    Nada AM; Younan MA
    Ther Adv Endocrinol Metab; 2021; 12():2042018821995364. PubMed ID: 33796252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Effectiveness and Impact on Insulin Therapy Cost After Addition of Dapagliflozin to Patients with Uncontrolled Type 2 Diabetes.
    Sosale B; Sosale A; Bhattacharyya A
    Diabetes Ther; 2016 Dec; 7(4):765-776. PubMed ID: 27761881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Korean Patients with Type 2 Diabetes Mellitus in Real-World Clinical Practice.
    Hong AR; Koo BK; Kim SW; Yi KH; Moon MK
    Diabetes Metab J; 2019 Oct; 43(5):590-606. PubMed ID: 30877709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of dapagliflozin on glycaemic control and other cardiovascular disease risk factors in type 2 diabetes mellitus: a real-world observational study.
    McGurnaghan SJ; Brierley L; Caparrotta TM; McKeigue PM; Blackbourn LAK; Wild SH; Leese GP; McCrimmon RJ; McKnight JA; Pearson ER; Petrie JR; Sattar N; Colhoun HM;
    Diabetologia; 2019 Apr; 62(4):621-632. PubMed ID: 30631892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics of Dapagliflozin Responders: A Longitudinal, Prospective, Nationwide Dapagliflozin Surveillance Study in Korea.
    Han E; Kim A; Lee SJ; Kim JY; Kim JH; Lee WJ; Lee BW
    Diabetes Ther; 2018 Aug; 9(4):1689-1701. PubMed ID: 29998370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Real DAPSI: A Real-World Retrospective Study on Assessing the Efficacy and Safety of a Fixed-Dose Combination of Dapagliflozin and Sitagliptin in the Indian Population.
    Bhattacharjee R; Rai M; Joshi P; Prasad A; Birla A
    Cureus; 2023 Oct; 15(10):e46767. PubMed ID: 37954782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates.
    Schubert A; Buchholt AT; El Khoury AC; Kamal A; Taieb V
    Curr Med Res Opin; 2017 Jun; 33(6):1155-1163. PubMed ID: 28323512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Dapagliflozin Therapy on Renal Protection and Kidney Morphology in Patients With Uncontrolled Type 2 Diabetes Mellitus.
    Sugiyama S; Jinnouchi H; Kurinami N; Hieshima K; Yoshida A; Jinnouchi K; Tanaka M; Nishimura H; Suzuki T; Miyamoto F; Kajiwara K; Jinnouchi T
    J Clin Med Res; 2018 Jun; 10(6):466-477. PubMed ID: 29707088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SGLT2 inhibitors as add on therapy in type 2 diabetes: a real world study.
    Tamez-Perez HE; Delgadillo-Esteban E; Soni-Duque D; Hernández-Coria MI; Tamez-Peña AL
    J Diabetes Metab Disord; 2017; 16():27. PubMed ID: 28680862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
    Frías JP; Guja C; Hardy E; Ahmed A; Dong F; Öhman P; Jabbour SA
    Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dulaglutide as an Add-on to Insulin in Type 2 Diabetes; Clinical Efficacy and Parameters Affecting the Response in Real-World Practice.
    Lee J; Cho YK; Kim HS; Jung CH; Park JY; Lee WJ
    Diabetes Metab Syndr Obes; 2019; 12():2745-2753. PubMed ID: 31920354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin.
    Nauck MA; Del Prato S; Durán-García S; Rohwedder K; Langkilde AM; Sugg J; Parikh SJ
    Diabetes Obes Metab; 2014 Nov; 16(11):1111-20. PubMed ID: 24919526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison betweeen dapagliflozin add-on therapy and insulin dose escalation in patients with uncontrolled type 2 diabetes treated with insulin: DVI study.
    Shin Y; Choi H; Lim S
    Diabetes Res Clin Pract; 2021 May; 175():108843. PubMed ID: 33933498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin.
    Bolinder J; Ljunggren Ö; Kullberg J; Johansson L; Wilding J; Langkilde AM; Sugg J; Parikh S
    J Clin Endocrinol Metab; 2012 Mar; 97(3):1020-31. PubMed ID: 22238392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.